Gregg Davis

Mr. Davis has nearly 30 years of experience in life sciences companies and has held roles of increasing responsibility including new product strategy and launch, marketing and business development. For the last 20 years, he has been focused on business and corporate development activities and has led the evaluation of over 100 deals ranging from research collaborations to marketing alliances to billion-dollar acquisitions, divestments and licensing agreements. Dozens of these transactions have closed including some of the pharmaceutical industries largest and most creative partnering deals.

Mr. Davis has worked with small, entrepreneurial companies in operational roles, as a venture capitalist and as co-founder of a cancer therapeutics company. He also has experience with large, multi-national companies. Mr. Davis joins Seed Therapeutics after serving as Senior Vice President of Business Development for AskBio where has closed gene therapy deals including R&D collaborations, company acquisitions, and licensing deals for several therapeutics and platform technologies. Prior to AskBio, he was Vice President of Corporate and Business development at Avadel Pharmaceuticals, headed Corporate Development at Patheon (now Thermo Fisher) and spent over 8 years leading transactions on GSK’s Worldwide Business Development team.

Gregg graduated with honors from Kenan Flagler Business School at The University of North Carolina where he previously received his BA in Economics.